The approval of Incyte Biosciences' Opzelura cream by the Medicines and Healthcare Products Regulatory Agency is a positive development for the company. This approval could lead to an increase in the company's market share and revenues as it allows the company to sell the product to a new patient group. Therefore, this news is likely to have a positive impact on the company's stock price in the short term.